Sodium‐glucose co‐transporter‐2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: Anationwide population‐based cohort study
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
Aims: To estimate the risk of diabetic ketoacidosis (DKA) associated with sodium‐glucose co‐transporter‐2 (SGLT2) inhibitor treatment compared with the risk associated with dipeptidyl‐peptidase‐4 (DPP‐4) inhibitor treatment. Methods: A nationwide population‐based cohort study using claims data from the Korean Health Insurance Review and Assessment Service from January 1, 2013 to June 30, 2017 was performed. A total of 56 325 patients who were started on SGLT2 inhibitors were included in this study and were matched with same number of patients who were started on DPP‐4 inhibitors using propensity score matching. Kaplan–Meier curves and Cox proportional hazards regression analyses were used to estimate the risk of hospitalization for DKA. Results: The risk of hospitalization for DKA was not increased in SGLT2 inhibitor users vs DPP‐4 inhibitor users (hazard ratio [HR] 0.956, 95% confidence interval [CI] 0.581‐1.572; P = .996). The incidence rate of hospitalization for DKA during the first 30 days after initiation of the SGLT2 inhibitor was 2.501 cases per 1000 person‐years, which was higher than the rate during 3 years (0.614 cases per 1000 person‐years). SGLT2 inhibitor use was associated with a higher HR in patients with diabetic microvascular complications (HR 2.044, 95% CI 0.900‐4.640; P = .088) and in patients taking diuretics (HR 3.648, 95% CI 0.720‐18.480; P = .118), although these associations were not statistically significant. Conclusion: We found that SGLT2 inhibitor treatment did not increase the risk of DKA compared with DPP‐4 inhibitor treatment. Our findings suggest that patients prescribed diuretics or those with microvascular complications may have a greater tendency to be hospitalized for DKA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655 · cited 2×
“41 per 1000 patient-years in the EMPA-REG OUTCOME trial).(3,8) Next, we used a DPP-4 inhibitor as an active comparator drug.”
BackgroundMethodHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134 · cited 3×
“In a recently published randomized controlled study, the EMPAREG OUTCOME trial, empagliflozin improved cardiovascular outcome, including hospitalization for heart failure and all-cause mortality,2 and was associated with slower progression of kidney disease.8 In the CANVAS programme, another randomized controlled stud…”
BackgroundResultCV Protection in the EMPA-REG OUTCOME Trial: A “Thrifty Substrate” Hypothesis
Ferrannini, E., Mark, M., & Mayoux, E. (2016) · Diabetes Care · doi:10.2337/dc16-0330 · Cited by 975
Peters, A. L., Buschur, E. O., Buse, J. B., Cohan, P., Diner, J. C., & Hirsch, I. B. (2015) · Diabetes Care · doi:10.2337/dc15-0843 · Cited by 849
Bonner, C., Kerr-Conte, J., Gmyr, V., Queniat, G., Moerman, E., Thévenet, J., Beaucamps, C., Delalleau, N., Popescu, I., Malaisse, W. J., et al. (2015) · Nature Medicine · doi:10.1038/nm.3828 · Cited by 670 · cited 1×
“Despite the protective effects of SGLT2 inhibitors on cardiovascular outcomes through ketogenesis, other studies have shown that SGLT2 inhibitor treatment may be a predisposing factor for DKA(4,17) through its actions increasing ketogenesis and triggering glucagon secretion by acting on pancreatic α cells.(18) The SGL…”
BackgroundMudaliar, S., Alloju, S., & Henry, R. R. (2016) · Diabetes Care · doi:10.2337/dc16-0542 · Cited by 571 · cited 1×
“Some studies have suggested that the use of ketone bodies as energy sources increases in SGLT2 inhibitor-treated patients, particularly in the heart and kidney, in response to increased ketogenesis.(10,14) The impact of SGLT2 inhibitor treatment on risk of DKA remains controversial.”
BackgroundRisk of diabetic ketoacidosis after initiation of an SGLT2 inhibitor
Fralick, M., Schneeweiss, S., & Patorno, E. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1701990 · Cited by 334 · cited 1×
“614 cases per 1000 personyears, respectively), similarly to a previous study.(6) This may be attributable to the insulinopenic tendencies of the patients who started the drug (ie, patients with marked β-cell insufficiency or adults with latent autoimmune diabetes); however, there were no laboratory test results, such…”
ResultKetoacidosis associated with SGLT2 inhibitor treatment: analysis of FAERS data
Blau, J. E., Tella, S. H., Taylor, S. I., & Rother, K. I. (2017) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.2924 · Cited by 271
Cited by
Santos-Gallego, C. G., Requena-Ibanez, J. A., San Antonio, R., Ishikawa, K., Watanabe, S., Picatoste, B., Flores, E., Garcia-Ropero, A., Sanz, J., Hajjar, R. J., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.056 · Cited by 651
Hamblin, P. S., Wong, R., Ekinci, E. I., Fourlanos, S., Shah, S., Jones, A. R., Hare, M. J. L., Calder, G. L., Epa, D. S., George, E. M., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00139 · Cited by 126
Lin, D. S.-H., Lee, J.-K., & Chen, W.-J. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgab274 · Cited by 97
Colacci, M., Fralick, J., Odutayo, A., & Fralick, M. (2022) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2021.04.006 · Cited by 94
Metadata
- Authors
- Kim, Y., Jeon, J. Y., Han, S. J., Kim, D. J., Lee, K., & Kim, H. J.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2018-04-14
- Volume
- 20
- Issue
- 8
- Pages
- 1852-1858
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2874659411
- Cited by
- 57
- References
- 10
- FWCI
- 4.95
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Sodium‐glucose co‐transporter‐2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: Anationwide population‐based cohort study. https://app.cochat.ai/papers/10.1111/dom.13297
- The paper
- Kim, Y., Jeon, J. Y., Han, S. J., Kim, D. J., Lee, K., & Kim, H. J. (2018). Sodium‐glucose co‐transporter‐2 inhibitors and the risk of ketoacidosis in patients with type 2 diabetes mellitus: Anationwide population‐based cohort study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.13297
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.